Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Sitagliptin, a CD26 (Dipeptidyl peptidase 4) (DPP4) inhibitors commonly used for type 2 diabetes, has shown remarkable potential in reducing acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT). A 2021 phase II trial demonstrated a substantial reduction in acute GVHD incidence compared to historical rates, with preserved graft-versus-leukemia effects and favorable safety outcomes
Farag et al. 2021 N…